A socio economic problem

Addiction is a huge
problem we try to solve.
The market is more than 3 billion USD and involves more than 35M people worldwide

Read More

Innovation research and development

With 20 years of experience,
we have developed new strategies to solve addiction problems

Read More

An effective treatment

Today, there is no real
solution to addiction.
Our first product,
KT-110,is a true chance of treatment.

Read More

European funds

Exceptional participation from Europe to finance clinical trials

Read More

Our mission : overcome the global challenge of addiction (alcohol, tobacco, cocaine, opioids… )

Kinnov-Therapeutics founders have worked on deciphering the pharmacological and biochemical mechanisms of addiction for more than 20 years, resulting in the identification of a disruptive strategy to treat addicted people. Indeed, addiction (alcohol, tobacco, gambling...) is becoming a serious socio-economic problem and for the sole US market, treatment of these pathologies reached $3 billion in 2013. Nevertheless, to date, few therapeutic agents are available and efficient on these pathologies of addiction.
Phase 2 study on safety and efficacy of KT-110 in alcohol use disorder is positive. Very High risk level population is likely to be targeted for phase 3 study. FDA accepts TAC reduction as main criterion, which provides consistency between USA and Europe for phase 3 study